Junshi Biosciences posts strong Q1 revenue growth and sharply reduced loss

An announcement from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.

Shanghai Junshi Biosciences has released an overseas regulatory announcement providing an English translation of its unaudited 2026 first-quarter financial report, prepared under PRC accounting standards for the STAR Market. The company reported operating income of RMB 726.3 million for the period, up 45.09% year-on-year, while narrowing its total loss to RMB 37.8 million from RMB 286.8 million a year earlier, and cautioned shareholders and potential investors to exercise care when trading its securities given the different reporting standards.

The board and senior management affirmed the accuracy and completeness of the disclosed financial data, jointly accepting legal responsibility for the information presented. This combination of strong revenue growth and a sharply reduced loss signals improving financial performance and may bolster investor confidence in the company’s progress toward profitability, despite the figures being unaudited and not prepared under IFRS.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company listed in Hong Kong and on Shanghai’s STAR Market. The firm operates in the biosciences and pharmaceutical industry, focusing on the development and commercialization of innovative drugs, with investors spanning both mainland China and international capital markets.

Average Trading Volume: 3,924,048

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$41.62B

Learn more about 1877 stock on TipRanks’ Stock Analysis page.